#Biotechnology #ArtificialIntelligence #Neurotechnology
nypost.com
Mad scientists to power AI data centers with living brain...
Scientists placed 200,000 living human brain cells on a microchip and taught it how to play a doomsday video game -- and are now using the dystopian tech to power AI data centers.
#HenriettaLacks #MedicalEthics #Biotechnology
edition.cnn.com
Novartis settles with Henrietta Lacks' estate over use of her 'stolen' cells to advance medicine
Novartis has settled a lawsuit by the estate of Henrietta Lacks that alleged the pharmaceutical giant unjustly profited off her cells, which were taken from her tumor without her knowledge in 1951 and reproduced in labs to enable major medical advancements, including the polio vaccine.
#Biotech #China #Pharmaceuticals
www.forbes.com
How China Became the Biotech Industry's Back-Office
Forbes contributors publish independent expert analyses and insights.
For years, public debate around U. S. dependence on China has focused on semiconductors, consumer electronics, rare earth minerals and industrial manufacturing.
#Biotechnology #Epilepsy #ConferenceCall
www.benzinga.com
Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026 - Bright Minds Biosciences (NASDAQ:DRUG)
- Conference Call and Live Webcast at 8AM ET -
NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc.
#Biotechnology #AutoimmuneDiseases #ClinicalTrials
www.nasdaq.com
Jade Biosciences To Report Phase I Trial Of JADE101 In 1H2026
(RTTNews) - Jade Biosciences, Inc. (JBIO), a clinical-stage biotechnology company developing therapies for autoimmune diseases, announced its 2026 strategic priorities on Monday, including anticipated milestones before the 44th Annual J.
#Biotechnology #RNAMedicines #HealthcareInnovation
www.benzinga.com
Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference - WAVE Life Sciences (NASDAQ:WVE)
CAMBRIDGE, Mass. , Jan. 05, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 44th Annual J.
#Osteoporosis #Biotech #ClinicalTrials
www.benzinga.com
Angitia Biopharmaceuticals Completes Enrollment of Phase 2 ARTEMIS Trial Evaluating AGA2118 for the Treatment of Osteoporosis
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter
- Company expects topline data from the study in 2027
WESTLAKE VILLAGE, Calif.
#Biotechnology #Healthcare #InflammatoryDiseases
www.benzinga.com
Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference - Upstream Bio (NASDAQ:UPB)
WALTHAM, Mass. , Jan. 05, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be presenting at the 44th Annual J.
#Biotech #Investing #Healthcare
www.barchart.com
ProPhase Labs Provides Update on Convertible Debt Conversions, Capital Structure, and Underlying Asset Value
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
UNIONDALE, NY, Jan.
#LeadershipTransition #Biotech #CorporateGovernance
www.benzinga.com
argenx Announces Leadership Transition Marking Next Evolution of Growth - argenx (NASDAQ:ARGX)
Tim Van Hauwermeiren to transition from CEO to Non-Executive Director and Chairman of Board of Directors and Karen Massey to transition from COO to CEO and Executive Director
January 5, 2026 7:00 a.
S
#Sustainability #SupplyChain #Biotechnology
www.streetinsider.com
WuXi Biologics Achieves ISO 20400 Certification, Setting Benchmark in Sustainable Procurement
WUXI, China, Jan. 4, 2026 /PRNewswire/ -- WuXi Biologics (2269. HK) announced it has achieved ISO 20400 Sustainable Procurement certification, an internationally recognized standard that integrates sustainability principles into procurement practices and promotes transparency and responsibility across the supply chain.
#Biotech #Pharmaceuticals #FDAApproval
seekingalpha.com
Corcept Therapeutics: Despite FDA Blind Side, Relacorilant Remains A Viable Drug (NASDAQ:CORT)
CORT's strong balance sheet enables pursuit of additional clinical evidence to address the FDA's concerns and potentially secure Relacorilant approval.
#Biotech #Obesity #Pharmaceuticals
www.forbes.com
How A Wall Street Analyst Started A $4 Billion Obesity Drug Company
Brian Lian founded publicly traded Viking Therapeutics to focus on metabolic diseases. With obesity drugs in development and the GLP-1 space booming, it's now a prime M&A target for giants jostling for their share of a potential $100 billion market.
